Riskpilot← Back to searchSign inGet full accessTribune Therapeutics AB
ABActiveOrg 5592811045Engelbrektsplan 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20200 employees
Revenue 2024
SEK 0
EBITDA margin
—
-37% vs 2023
Equity ratio
46.8%
Financial strength
Net profit 2024
SEK -61M
-60% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -31,5M | -37% |
| Net profit | SEK -61M | -60% |
| Total assets | SEK 17,4M | -75% |
| Equity | SEK 8,1M | -88% |
| Employees | 0 | — |
Legal name
Tribune Therapeutics AB
Org number
5592811045
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4 november 2020
Share capital
SEK 219 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av Baker, Christopher Michael Ilicki, Jonathan Jossi Koistinaho, Milla Maria Odlander, Björn Ingemar Ribas De Almeida, João Carlos Firman tecknas av en av Hansson, Karl Jonas Schambye, Hans Thalsgård i förening med en av Baker, Christopher Michael Ilicki, Jonathan Jossi Koistinaho, Milla Maria Odlander, Björn Ingemar Ribas De Almeida, João Carlos
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, bedriva forskning och utveckling, tillverkning, marknadsföring, försäljning och licensiering av läkemedel som kan användas för att bland annat behandla fibrotiska sjukdomar, samt att bedriva därmed förenlig verksamhet.
Address
Engelbrektsplan 1
Email
georg.beiske@healthcap.eu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | −2 734 | — |
| EBITDA | −7 663 | −28 530 | −23 066 | −31 507 |
| Depreciation & amort. | −0 | −0 | — | −0 |
| EBIT | −7 663 | −28 530 | −23 066 | −31 507 |
| Net financials | −6 726 | −10 131 | −15 188 | −29 516 |
| Profit before tax | −10 969 | −38 661 | −38 254 | −61 023 |
| Tax | −0 | −0 | — | −0 |
| Net profit | −10 969 | −38 661 | −38 254 | −61 023 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 15 837 | 33 324 | 68 419 | 17 357 |
| Equity | 14 024 | 25 868 | 65 284 | 8 123 |
| Long-term debt | 0 | 0 | — | 0 |
| Short-term debt | 1 813 | 7 456 | 3 135 | 9 234 |
| Total debt | 1 813 | 7 456 | 3 135 | 9 234 |
EBITDA margin
-3150700000.0%
This company
15.8%
Market median
-19941139341% vs market
20212024
Equity ratio
46.8%
This company
38.2%
Market median
+23% vs market
20212024
Return on equity
-751.2%
This company
18.4%
Market median
-4183% vs market
20212024
Net profit margin
-6102300000.0%
This company
8.1%
Market median
-75337037137% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
1.14×
This company
0.62×
Market median
-84% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JT Chief Auditor | Chief Auditor | 2022 |
| Former (2) | ||
GA Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
AK Chief Auditor | Chief Auditor | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (7) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2021 | |
| Board of Directors | 2025 | |
| Board of Directors | 2023 | |
| Board of Directors | 2025 | |
| Chairman | 2021 | |
| Former (7) | ||
| Deputy Board Member | 2021 – 2021 | |
| Deputy Board Member | 2021 – 2021 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2021 – 2025 | |
| Board of Directors | 2022 – 2025 | |
| Board of Directors | 2021 – 2021 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Tribune Therapeutics AB (this company)
Tribune Therapeutics ASTRIBUNE THERAPEUTICS ASTribune Therapeutics ASBoard members of Tribune Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Georg Anton Vo Beiske | Chief Executive Officer | 0 companies |
| Anna Kristina Svanberg | Chief Auditor | 0 companies |
| Jakob Tomas Christoffer Grunditz | Chief Auditor | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Ole Jørgen Kaasbøll | Board of Directors | 0 companies |
| Jørgen Søberg Petersen | Board of Directors | 0 companies |
| Björn Ingemar Odlander | Board of Directors | 0 companies |
| Christopher Michael Baker | Board of Directors | 0 companies |
| Ilias Papatheodorou | Board of Directors | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| João Carlos Ribas De Almeida | Board of Directors | 0 companies |
| Jonathan Jossi Ilicki | Board of Directors | 0 companies |
| Milla Maria Koistinaho | Board of Directors | 0 companies |
| Hans Thalsgård Schambye | Board of Directors | 0 companies |
| Jacob Uno Stanley Gunterberg | Board of Directors | 0 companies |
| Karl Jonas Hansson | Chairman | 0 companies |